Muhammad Umair Mushtaq: Cellular Therapies Hold Promise in The Future of Melanoma Care
Muhammad Umair Mushtaq, Associate Professor Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center, shared a post on X:
“Cellular Therapies Hold Promise in The Future of Melanoma Care.”
At the 2025 Immune Cell Effector Therapy (ICE-T) Conference, Muhammad Umair Mushtaq, MD, discussed the current state of tumor-infiltrating lymphocyte (TIL) therapy in metastatic melanoma, with a focus on lifileucel (Amtagvi). He highlighted results from a phase 2 trial (NCT02360579) in which lifileucel achieved an overall response rate of 36% in heavily pretreated patients.
Among 66 participants who had previously received immune checkpoint inhibitors and BRAF/MEK inhibitors, there were 2 complete responses and 20 partial responses, demonstrating meaningful clinical activity in this difficult-to-treat population.
Mushtaq, an associate professor at the University of Kansas Medical Center, emphasized strategies to further improve outcomes with cellular therapies. He noted that earlier use of TIL therapy, particularly in the first-line setting where disease burden is lower, may enhance efficacy.
He also pointed to the promise of combination approaches, such as pairing cellular therapies with T-cell engagers or other forms of immunotherapy, to expand their impact in melanoma treatment.
More posts featuring Muhammad Umair Mushtaq.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023